Licensing Agreement Hopes to Advance Treatment for Sickle Cell Patients
Cincinnati Children’s and Calimmune Inc. have announced a license agreement to develop and commercialize a gene therapy discovered by Punam Malik, MD, the Marjory J. Johnson chair of gene and cell therapy, and director of the comprehensive sickle cell program at Cincinnati Children’s.
The hope is that this therapy produces safe and effective results in the Phase I/II clinical trial that is currently enrolling patients and then continues to a successful Phase III clinical trial. Following a successful Phase III trial, the therapy would go through required regulatory approvals in the US and abroad.
Read more from the Cincinnati Enquirer.